Exhibit 99.1
Company Contact: | Investor Contact: | Agency Contact: |
David Snyder | Stephen Bassett | Heather Smith |
Axcelis Technologies, Inc. | Axcelis Technologies, Inc. | Loomis Group |
Tel: +1 (978) 787 4273 | Tel: +1 (978) 787 4000 | Tel: +1 (617) 309 8005 |
Fax: +1 (978) 787 4275 | Fax: +1 (978) 787 9133 | Fax: +1 (617) 638 0033 |
david.snyder@axcelis.com | investor.relations@axcelis.com | smithh@loomisgroup.com |
AXCELIS ANNOUNCES FINANCIAL RESULTS
FOR SECOND QUARTER 2007
BEVERLY, Mass. — August 1, 2007 — Axcelis Technologies, Inc. (Nasdaq: ACLS) today announced financial results for the second quarter ended June 30, 2007. The Company reported revenues of $110.1 million, compared to $97.5 million for the first quarter of 2007. Net income for the second quarter was $4.7 million, or $0.05 per share, compared to net income for the first quarter of 2007 of $2.7 million, or $0.03 per share. In the corresponding quarter for the previous year, the Company reported revenues of $117.6 million and net income of $12.1 million, or $0.12 per share.
Commenting on the Company’s performance, Chairman and CEO Mary Puma said, “We continue to receive positive feedback from customers on advanced technology development and production manufacturing being run on our Optima HD, despite the softening industry conditions. We are confident that continued progress will drive growth of our high dose implant business as we secure additional orders through design wins and capacity buys. Additionally, we were able to win another high volume capacity order for our dry strip products, strengthening our position in the cleaning space. We look forward to this trend continuing.”
Second Quarter Detail
Shipments and Margins
Shipments before provision for deferred revenue for the second quarter totaled $116.3 million. Geographically, Axcelis’ systems shipments for the quarter were to: Asia, 59%; North America, 29%; and Europe; 12%. The ion implantation business accounted for 76% of total shipments in the second quarter, while other products (dry strip, curing, and RTP) accounted for 24%. Gross margin for the second quarter was 39.6%.
Orders and Backlog
Orders (new systems bookings and service) received for the second quarter totaled $75.8 million. New systems bookings, excluding service, amounted to $34.5 million. Backlog plus deferred systems revenue at quarter end was $93.4 million. Backlog consists of systems only (i.e., excluding service contracts) that are generally scheduled to ship within six months.
SEN Corporation, an SHI and Axcelis Company (“SEN”)
Axcelis owns 50% of SEN, a Japanese company that is licensed to make and sell certain Axcelis ion implanters in Japan. SEN’s revenue for the second quarter totaled $55.2 million.
Business Outlook
Axcelis’ financial outlook for the third quarter of 2007 includes revenues in the range of $110 million to $120 million. Gross margins in the third quarter are expected to be slightly below second quarter levels as a result of revenue recognition on new products. The Company forecasts third quarter earnings per share of approximately $0.02. Axcelis assumes no responsibility to update guidance. Axcelis will only confirm or update guidance via a press release.
Second Quarter 2007 Conference Call
The Company will be hosting a conference call today, Wednesday, August 1, 2007, beginning at 5:00 pm ET. The purpose of the call is to discuss second quarter results and to provide guidance for the third quarter of 2007.
The call will be available to interested listeners via an audio webcast that can be accessed through Axcelis’ home page at www.axcelis.com, or by dialing 1-800-479-1628 (1-719-457-2729 outside North America). Participants calling into the conference call will be requested to provide the company name: Axcelis Technologies, the conference leader: David Snyder, and pass code: #1476171. A webcast replay will be available from 8:00 pm ET on August 1, 2007 until 5:00 pm ET September 1, 2007.
Safe Harbor Statement
This document contains forward-looking statements under the SEC safe harbor provisions. These statements, which include our guidance for future financial performance, are based on management’s current expectations and should be viewed with caution. They are subject to various risks and uncertainties, many of which are outside the control of the Company, including the timing of orders and shipments, the conversion of orders to revenue in any particular quarter, or at all, our ability to implement successfully our profit plans, the continuing demand for semiconductor equipment, relative market growth, continuity of business relationships with and purchases by major customers, competitive pressure on sales and pricing, increases in material and other production costs that cannot be recouped in product pricing and global economic, political and financial conditions. These risks and other risk factors relating to Axcelis are described more fully in the most recent Form 10-K filed by Axcelis and in other documents filed from time to time with the Securities and Exchange Commission.
About Axcelis Technologies, Inc.
Axcelis Technologies, Inc., headquartered in Beverly, Massachusetts, provides innovative, high-productivity solutions for the semiconductor industry. Axcelis is dedicated to developing enabling process applications through the design, manufacture and complete life cycle support of ion implantation, rapid thermal processing, and cleaning and curing systems. Axcelis also licenses its 50% owned joint venture, SEN Corporation, an SHI and Axcelis Company, to manufacture and sell certain implant products in Japan. The company’s Internet address is: www.axcelis.com.
